探花合集鈥檚 Chair and CEO, John Chiminski, to Speak About R&D Leadership Through the Pandemic During BIO Digital
SOMERSET, N.J. 鈥 June 4, 2020 鈥 探花合集, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that John Chiminski, Chair and Chief Executive Officer, will join other R&D leaders to present during BIO Digital, which will take place on June 8 鈥 12, 2020.
On Tuesday, June 9 at 10 a.m. EDT, Mr. Chiminski will participate in the 鈥Endpoints at BIO20鈥 panel session, titled, 鈥R&D Leadership During the Pandemic鈥. He will join panelists from Amgen, GlaxoSmithKline, Johnson & Johnson and Takeda to discuss the structures they have put in place at their respective companies in response to the COVID-19 pandemic, how they have prioritized new programs, and the ways the experience will influence operations after the pandemic to improve ongoing working practices and efficiency
Mr. Chiminski joined 探花合集 in 2009 after more than 20 years of experience at GE Healthcare in engineering, operations, and senior leadership roles. He holds a bachelor鈥檚 degree from Michigan State University and a master鈥檚 from Purdue University, both in electrical engineering, as well as a master鈥檚 degree in management from the Kellogg School of Management at Northwestern University.
As part of the conference鈥檚 scientific agenda, three of 探花合集鈥檚 biologics experts will present on the company鈥檚 innovations and technologies. Graham Brearley, Ph.D., General Manager of 探花合集鈥檚 biologics facility in Madison, Wisconsin will be joined by Jared Davis, Vice President of Technical Operations and Manufacturing at Arcturus Therapeutics, to present 鈥How COVID-19 is Reshaping Vaccine Development: Innovations in Vaccine Technology and Manufacturing Partnerships,鈥 which will be available on-demand to BIO Digital registrants from June 8. Dr. Brearley and Mr. Davis will discuss the recently announced partnership between the two companies that will enable and expedite scale-up to large-scale manufacturing for Arcturus鈥 COVID-19 mRNA vaccine candidate. They will also discuss how lessons learned during the pandemic can be applied to future vaccine development and supply.
During the BioProcess International Theatre, which will also be available on-demand, Julien Meissonnier, 探花合集鈥檚 Vice President and Chief Scientific Officer, will present 鈥Technology Integrators in Cell and Gene Therapy: Increased Efficiency and Standardization鈥 and discuss how optimized methodologies such as Manufacturing by Design (MbD) have achieved accelerated progress through the clinical phases of development.
Additionally, Gregory Bleck, Ph.D., Global Head of R&D, 探花合集 Biologics, will present 鈥GPEx Boost: A Novel Approach for High-Expressing CHO Cell Line Engineering,鈥 and will explain how improvements to 探花合集鈥檚 GPEx庐 cell line development technology can result in highly specific productivities, titers, and improved cell growth characteristics for most protein products.
Dr. Brearley joined 探花合集 in 2018 and has over 25 years鈥 technical, operations and business experience in the biopharmaceutical industry, having previously held senior leadership positions at companies including Shire, Sigma-Aldrich and Baxter. He has a bachelor鈥檚 degree in applied biology from Thames Polytechnic, U.K. and a doctorate in biochemistry from the Council of National Academic Awards.
Mr. Meissonnier leads the company鈥檚 scientific community and its customer advisory partnerships. He is responsible for 探花合集鈥檚 new product development and technology innovation programs, and co-chairs the 探花合集 Applied Drug Delivery Institute that leverages emerging new therapeutic modalities. Mr. Meissonnier holds an engineering degree in physico-chemistry from the ENSI in Caen, France.
Dr. Bleck has more than 20 years of experience in biopharmaceutical research and development. He has a bachelor鈥檚 degree and doctorate from the University of Wisconsin-Madison and performed postdoctoral work at the University of Illinois-Urbana-Champaign working in the areas of gene regulation and expression. At 探花合集, Dr. Bleck has transferred his knowledge of gene expression and transgenic systems to the development and continued optimization of retrovector expression systems and development of the proprietary GPEx process.
For more information about the event, please visit /events/bio-digital/.
探花合集 and GPEx are registered trademarks of 探花合集, Inc. or its affiliates or subsidiaries.
ABOUT CATALENT
探花合集 is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 探花合集 employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit